Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | LGMN | Q99538 | 1/20 | 0.30 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682009 | 0.79 | PNMT (0.37) | ALDH1A1MEN1KMT2AMMP13PSIP1 | |
| SCHEMBL2446368 | 0.78 | PSIP1 (0.60) | ALDH1A1MEN1KMT2AMMP13PSIP1 | |
| SCHEMBL11005081 | 0.78 | MMP13 (0.40) | ALDH1A1MEN1KMT2AMMP13HSD11B1 | |
| SCHEMBL159760 | 0.78 | PSIP1 (0.58) | ALDH1A1MEN1KMT2AGAAPSIP1 | |
| SCHEMBL507150 | 0.77 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AMMP13GAA | |
| SCHEMBL7684910 | 0.76 | MEN1 (0.34) | ALDH1A1MEN1KMT2AMMP13 | |
| SCHEMBL25385935 | 0.75 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AMMP13GAA | |
| SCHEMBL10453838 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMMP13GAA | |
| SCHEMBL10266898 | 0.75 | PLCG1 (0.59) | ALDH1A1MEN1KMT2AMMP13GAA | |
| SCHEMBL2916646 | 0.75 | KMT2A (0.53) | ALDH1A1MEN1KMT2AMMP13GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678907-B2 | Halogenation of rylen-carboximides with elementary halogen in a two-phase mixture comprising an organic solvent and water, wherein formed halogen hydroxide is continuously removable from the organic solvent | BASF AKTIENGESSELLSCHAFT (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1802622-B1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | BASF AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1802622-A1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037539-A1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | CYP8B1, HACL2, CTRB2 | ALDH1A1 1379/4885MEN1 2805/4885KMT2A 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.